VAN ROMPAEY, Luc,MOSHIR, Mahan,ZABROCKI, Piotr,DELAHAYE, Tim
申请号：
AU2019209503
公开号：
AU2019209503A1
申请日:
2019.01.16
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The present disclosure relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1 R3/IL1 RAP and CD47.
